Research We Fund
 Many people living today with MS remember a time when nothing
could be done to control their disease. That changed in the
1990s with the introduction of the first disease modifying
therapies (DMT) for MS. These medications — the beta-interferons, glatiramer acetate and natalizumab — have
revolutionized the management of MS.
Doctors can now offer many of their MS patients a number of treatment options to reduce MS relapses and slow the progression of their disease. The advent of DMTs has also provided important insights into the underlying disease processes at work in MS. Over the past 15 years there has been an explosion of new research into what causes MS, how it develops, and why it progresses.
Canadian researchers have been in the vanguard of this research revolution, with pioneering work in genetics, pediatric MS, and stem cell research. Since its founding in 1948, the Multiple Sclerosis Society of Canada has acted as a key partner to the MS research community. In its first 60 years, donors to the Society have made it possible to provide over $110 million in funding for Canada’s world-class researchers, enabling them to explore new ideas and participate in international clinical trials of new medications. The Society also provides vital seed money for new avenues of research, and promotes the development of the next generation of scientists and clinicians working to find a cure for MS. The MS Society now provides over $10 million per year to MS research.
The MS Society also funds the MS Scientific Research Foundation, which supports large collaborative scientific projects. Over the next three years, the Foundation will spend another $12 million on MS research.
Research Summaries
Select the links below to view PDF versions of the most recent Research Summaries:
» 2012 Research Summaries
Back to top
|
